Product categories: In vitro medical device / Digital platform / Biomarkers
ARTIDIS AG has developed first ever nanomechanical biomarker for diagnosing cancer and is applying its technology platform of precise tissue measurement in combination with data analytics (up to 180 clinical parameters per patient) to personalize diagnosis and treatment results. ARTIDIS technology is currently being validated in a blinded clinical study on more than 500 patients at the University Hospital, Basel for breast cancer. End of 2019 ARTIDIS will launch a multi-centre study (Europe, US) to test its platform in a neoadjuvant therapy setting for breast and lung cancer. Also ARTIDIS currently runs a feasibility study with a large pharma for drug development beyond oncology.
Contact: Marija Plodinec, email@example.com
- BIO International Convention 2019